减重神药不再“一家独大”？清华团队一针见效新技术问世，改造免疫细胞带来持久控糖瘦身双效

Core Viewpoint - The article discusses a groundbreaking research study that introduces a long-lasting CAR-T cell platform for the delivery of biologics, specifically targeting chronic diseases like obesity and diabetes, offering a potential single-dose treatment solution [7][8][20]. Group 1: Research Breakthroughs - The research team from Tsinghua University developed a revolutionary long-lived CAR-T cell, named GD2TIF, which can deliver GLP-1 for obesity and diabetes treatment with a single injection, maintaining long-term effects [8][18]. - The study published in Nature Communications on August 29, 2025, highlights the potential of GD2TIF cells to provide a "one-time treatment, long-term effectiveness" solution for chronic diseases [9][20]. - Previous methods, such as using AAV vectors for gene delivery, have limitations in providing long-term therapeutic effects due to their transient nature [9][10]. Group 2: Mechanism and Efficacy - GD2TIF cells can secrete GLP-1, achieving sustained weight maintenance and normal blood sugar levels in obesity mouse models, thus meeting clinical "cure" standards [18][20]. - The research emphasizes the importance of selecting GD2 as a target, as it is highly expressed in certain tumors but minimally in normal tissues, reducing the risk of off-target effects [16][17]. - The innovative approach of using CAR-T cells as "living factories" for therapeutic proteins aims to address the challenges of traditional biologic treatments that require frequent injections [10][11]. Group 3: Future Implications - The successful development of GD2TIF cells as a reliable platform for biologic delivery could revolutionize treatment for various chronic diseases, potentially reducing the burden of continuous medication and frequent medical visits for patients [20]. - The article notes that while the cost of CAR-T cell therapy remains high, advancements in cell therapy technology and scalable production could make this long-term delivery method more cost-effective compared to traditional repeated injections [20].